In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on BioCardia (BCDA – Research Report), with a price target of $9.00. The company’s shares opened today at $1.32.
According to TipRanks, Pantginis is an analyst with an average return of -2.8% and a 36.27% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Panbela Therapeutics, Celldex, and Onconova Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioCardia with a $9.00 average price target.
See the top stocks recommended by analysts >>
BCDA market cap is currently $40.49M and has a P/E ratio of -3.04.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BCDA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.
Read More on BCDA:
- BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected
- BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan’s Pharmaceutical Medical Device Agency
- BioCardia completes submission of CardiAMP Cell Therapy System in Japan
- BioCardia prices 1.13M shares registered direct offering at $2.336 per share
- BioCardia enters into purchase agreement to sell 1.13M shares at $2.336
